Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

Figure 1

Generation of primary human T cells expressing costimulated ligand for redirectionagainst tumor antigens via bispecific antibody. A. Upper left Schematic representing the costimulated ligand; BsAb-IR. Upper right Schematic representation of Folate Receptor alpha based BsAB-Immune Receptor gene constructs containing extracellular portion of FRa (231aa) fused to the human CD3z cytosolic domain alone (BsAb-IR-z) or in combination with the CD28 co-stimulatory module (BsAb-IRFBIR-28z). B. BsAb-IR transgene expression (open histograms) was detected by Mov18/ZEL antibody (Enzo Life Sciences) followed by anti-mouse FITC or and via GFP expression for control, GFP transduced T-cells. Staining was performed 5 days following transduction with lentivirus and compared to untransduced T cells, or isotype stained T cells (grey filled histograms). Percent transduction is indicated.

Back to article page